Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

1.

A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.

Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS.

Dig Dis Sci. 2006 Jun;51(6):1033-8.

PMID:
16865563
[PubMed - indexed for MEDLINE]
2.

Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.

Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP.

J Clin Oncol. 1999 Oct;17(10):3270-5.

PMID:
10506629
[PubMed - indexed for MEDLINE]
3.

A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.

Lee DH, Kim HT, Han JY, Lee SY, Yoon SJ, Kim HY, Lee JS.

Cancer Chemother Pharmacol. 2008 Jan;61(1):83-8. Epub 2007 Apr 28.

PMID:
17468871
[PubMed - indexed for MEDLINE]
4.

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P.

Br J Cancer. 1999 Dec;81(8):1351-5.

PMID:
10604732
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.

Gilbert J, Cmelak A, Shyr Y, Netterville J, Burkey BB, Sinard RJ, Yarbrough WG, Chung CH, Aulino JM, Murphy BA.

Cancer. 2008 Jul 1;113(1):186-92. doi: 10.1002/cncr.23545.

PMID:
18484593
[PubMed - indexed for MEDLINE]
Free Article
6.

A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.

Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M.

Cancer Chemother Pharmacol. 2007 Jun;60(1):1-6. Epub 2007 Mar 29.

PMID:
17393168
[PubMed - indexed for MEDLINE]
7.

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS.

J Clin Oncol. 2006 Jan 20;24(3):401-6.

PMID:
16421420
[PubMed - indexed for MEDLINE]
Free Article
8.

Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.

Saito H, Kudoh S, Nakagawa K, Negoro S, Matsui K, Semba H, Takada M.

Am J Clin Oncol. 2006 Oct;29(5):503-7.

PMID:
17023787
[PubMed - indexed for MEDLINE]
9.

Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.

Hainsworth JD, Spigel DR, Litchy S, Greco FA.

J Clin Oncol. 2006 Aug 1;24(22):3548-54.

PMID:
16877720
[PubMed - indexed for MEDLINE]
Free Article
10.

Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.

Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N.

Jpn J Clin Oncol. 2010 Apr;40(4):313-8. doi: 10.1093/jjco/hyp173. Epub 2010 Jan 4.

PMID:
20047862
[PubMed - indexed for MEDLINE]
Free Article
11.

Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.

Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, Nakagawa K, Takada M, Negoro S, Tamura K, Ando M, Tada T, Fukuoka M; West Japan Thoracic Oncology Group 9902.

J Clin Oncol. 2006 Nov 20;24(33):5247-52.

PMID:
17114657
[PubMed - indexed for MEDLINE]
Free Article
12.

Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.

Kim HG, Lee GW, Kang JH, Kang MH, Hwang IG, Kim SH, Hahm JR, Jeong YY, Kim HC, Lee JD, Lee JS, Hwang YS.

Lung Cancer. 2008 Aug;61(2):220-6. doi: 10.1016/j.lungcan.2007.12.020. Epub 2008 Feb 12.

PMID:
18272249
[PubMed - indexed for MEDLINE]
13.

Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.

Langer CJ, Somer R, Litwin S, Feigenberg S, Movsas B, Maiale C, Sherman E, Millenson M, Nicoloau N, Huang C, Treat J.

J Thorac Oncol. 2007 Mar;2(3):203-9.

PMID:
17410043
[PubMed - indexed for MEDLINE]
14.

Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.

Lee JE, Park HS, Jung SS, Kim JO, Kim SY.

Oncology. 2007;73(1-2):76-80. doi: 10.1159/000120632. Epub 2008 Mar 12.

PMID:
18334853
[PubMed - indexed for MEDLINE]
15.

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.

Hong YS, Lee HR, Park S, Lee SC, Hwang IG, Park BB, Lee J, Ahn JS, Ahn MJ, Lim HY, Park K.

Br J Cancer. 2006 Dec 18;95(12):1648-52. Epub 2006 Nov 28.

PMID:
17133266
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience.

Hatton MQ, Reed NS.

Clin Oncol (R Coll Radiol). 1997;9(6):385-9.

PMID:
9448967
[PubMed - indexed for MEDLINE]
17.

Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.

Ku GY, O'Reilly EM, Saltz LB, Schrag D, Maki RG, Kelsen DP, Ilson DH.

Cancer Invest. 2009 May;27(4):402-6. doi: 10.1080/07357900802406327.

PMID:
19219674
[PubMed - indexed for MEDLINE]
18.

Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.

Nakano K, Takahashi S, Yuasa T, Nishimura N, Mishima Y, Sakajiri S, Yokoyama M, Tsuyama N, Ishikawa Y, Hatake K.

Jpn J Clin Oncol. 2012 Aug;42(8):697-703. doi: 10.1093/jjco/hys085. Epub 2012 Jun 13.

PMID:
22701038
[PubMed - indexed for MEDLINE]
Free Article
19.

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.

Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK.

Cancer. 2001 Sep 1;92(5):1101-7.

PMID:
11571721
[PubMed - indexed for MEDLINE]
20.

Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.

Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H.

Jpn J Clin Oncol. 2007 Sep;37(9):686-91. Epub 2007 Aug 24.

PMID:
17720736
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk